PDS Biotech Reports Third Quarter 2026 Financial Results

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PDS Biotech Reports Third Quarter 2026 Financial Results PRINCETON, N.J., November 13, 2026 -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company focused on transforming how the immune system targets

Event · Earnings
Original reporting
Published Nov 13, 2026, 1:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 1:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PDSB
Neutral
high confidence
Mentioned
$PDSB
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PDSBNeutralMed
01

Why it matters

The filing provides the first public view of Q3 2026 results and a fresh capital raise, offering traders fresh data to price the stock.

02

Market read

The results and financing are material for PDSB's valuation and may influence micro‑cap biotech sentiment.

03

What to watch

The new patents in Japan, India and Israel broaden IP protection, which may enhance future partnership valuations.

Relevance 7/10Novelty 7/10Timing: today
AlphAI · Earnings readPDSB · Q3 2026 · ended 2026-09-30

PDS Biotech cuts quarterly R&D and operating expenses, narrows net loss to $7.6 million, and reports $15.2 million in cash at September 30, 2026

→Mixed quarter

Quarterly operating expenses and net loss fell year over year, with R&D down $2.5 million. Cash fell from $26.7 million at December 31, 2025 to $15.2 million at September 30, 2026, net interest expense rose to $1.7 million, the filing names a going concern risk, and no guidance was issued.

EPS · GAAP
$0.11

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net loss, three months ended September 30, 2026GAAP$7.6M––
Net loss per share, basic and diluted, three months ended September 30, 2026GAAP$0.11––
Research and development expenses, three months ended September 30, 2026GAAP$2.1M–decrease of $2.5 million
General and administrative expenses, three months ended September 30, 2026GAAP$3.8M–increase of $0.2 million
Total operating expenses, three months ended September 30, 2026GAAP$5.9M––
Loss from operations, three months ended September 30, 2026GAAP$(5,896,104)––
Interest income, three months ended September 30, 2026GAAP$41,630––
Interest expense, three months ended September 30, 2026GAAP$(1,766,451)––
Net interest income (expense), three months ended September 30, 2026GAAP$1.7 million net interest expense––
Benefit from income taxes, three months ended September 30, 2026GAAP-––
Research and development expenses, nine months ended September 30, 2026GAAP$8,773,832––
General and administrative expenses, nine months ended September 30, 2026GAAP$10,140,094––
Total operating expenses, nine months ended September 30, 2026GAAP$18,913,926––
Interest income (expense), net, nine months ended September 30, 2026GAAP$(5,806,630)––
Loss before income taxes, nine months ended September 30, 2026GAAP$(24,720,556)––
Benefit from income taxes, nine months ended September 30, 2026GAAP-––
Net loss, nine months ended September 30, 2026GAAP$(24,720,556)––
Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP$(0.40)––
Cash and cash equivalents at September 30, 2026GAAP$15.2M––
Total assets at September 30, 2026GAAP$18,571,942––
Total stockholders' equity at September 30, 2026GAAP$13,495,140––

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • The company announced the initial closing of a PIPE financing of up to $22.3 million led by Nant Capital, LLC with additional participation from current investors. The filing says the initial closing was completed this quarter but does not state the amount of that initial closing.
  • The PIPE includes a contingent milestone closing triggered by the Company's submission to the FDA of a registrational Phase 3 clinical trial protocol for PDS0301, subject to the satisfaction or waiver of applicable closing conditions.
  • In connection with the PIPE, the Company entered into an option agreement granting NantWorks, LLC a one-year exclusive right to negotiate an exclusive license for the PDS0101 program.

What drove it

  • The company attributes the R&D decrease of $2.5 million primarily to decreases of $1.6 million in clinical trial costs, $0.6 million in personnel costs and $0.3 million in manufacturing costs.
  • The company attributes the G&A increase of $0.2 million primarily to an increase of $0.3 million in professional fees and an increase of $0.1 million in personnel costs, offset by a decrease of $0.2 million in stock based compensation costs.
  • Net interest expense was $1.7 million for the quarter versus $0.9 million a year earlier. Gross interest expense was $1,766,451 versus $1,150,378, and interest income was $41,630 versus $281,109. The filing does not give a reason for these changes.
  • Net loss for the nine months was $(24,720,556) versus $(26,932,586). The prior-year nine-month period included a benefit from income taxes of $1,169,820, which the current period does not show.

Concerns

  • Cash and cash equivalents fell from $26,711,969 at December 31, 2025 to $15,245,081 at September 30, 2026.
  • The forward-looking statements list the company's ability to continue as a going concern and its dependence on additional financing as risk factors.
  • Net interest expense increased to $1.7 million from $0.9 million, and gross interest expense increased to $1,766,451 from $1,150,378.
  • Long-term debt was $11,733,350 at December 31, 2025 and is shown as '-' at September 30, 2026. The filing does not explain the change.
  • Weighted average shares outstanding rose to 71,936,955 for the quarter from 46,869,531 a year earlier, which increases the dilution base for per-share results.
  • The forward-looking statements list the company's ability to regain and maintain compliance with Nasdaq continued listing requirements, including the minimum bid price requirement, and the risk of delisting.

What to watch

  • Closing of the PIPE financing: the amount of the initial closing and the timing and conditions of the contingent milestone closing tied to submission of a registrational Phase 3 protocol for PDS0301 to the FDA.
  • Cash runway: cash of $15,245,081 at September 30, 2026 against quarterly net loss of $7.6 million and net interest expense of $1.7 million.
  • The one-year NantWorks option to negotiate an exclusive license for PDS0101, and the company's stated intent to pursue strategic partnerships or other externally funded opportunities for PDS0101 Phase 3 development.
  • The status of the going concern language and the Nasdaq minimum bid price requirement.
  • Clinical progress for PDS0301 at the NCI and in the Phase 2 trials discussed at the KOL event.
  • Interest expense trend, given the change from $1,150,378 to $1,766,451 and the removal of long-term debt from the balance sheet.

Balance sheet and cash flow

  • Cash and cash equivalents: $15,245,081 at September 30, 2026 versus $26,711,969 at December 31, 2025.
  • Working capital: $13,297,920 at September 30, 2026 versus $18,770,871 at December 31, 2025.
  • Total assets: $18,571,942 at September 30, 2026 versus $30,494,083 at December 31, 2025.
  • Long-term debt: none at September 30, 2026 (printed as '-') versus $11,733,350 at December 31, 2025. The filing does not state how this balance was settled or reclassified.
  • Accumulated deficit: $(241,327,060) at September 30, 2026 versus $(216,606,504) at December 31, 2025.
  • Total stockholders' equity: $13,495,140 at September 30, 2026 versus $9,251,833 at December 31, 2025.
  • Weighted average common shares outstanding, basic and diluted: 71,936,955 for the three months ended September 30, 2026 versus 46,869,531 for the same period of 2025. For the nine months: 61,145,055 versus 44,648,508.
  • The filing contains no operating cash flow, investing cash flow or free cash flow figures.

Analysis

PDS Biotech reported a third-quarter 2026 net loss of $7.6 million, or $0.11 per basic and diluted share, against $9.0 million, or $0.19 per share, a year earlier. The company's own explanation for the lower operating spend is in its R&D and G&A commentary. R&D fell to $2.1 million from $4.6 million, a decrease of $2.5 million, which the filing primarily attributes to lower clinical trial costs of $1.6 million, personnel costs of $0.6 million and manufacturing costs of $0.3 million. G&A rose to $3.8 million from $3.6 million, which the filing attributes mainly to higher professional fees of $0.3 million. Total operating expenses declined to $5.9 million from $8.1 million, and the nine-month figures show the same direction, with R&D at $8,773,832 against $14,620,308 and total operating expenses at $18,913,926 against $24,869,251.

Below the operating line, the quarter's result was pressured by financing costs. Net interest expense was $1.7 million against $0.9 million a year earlier, with gross interest expense of $1,766,451 against $1,150,378 and interest income of $41,630 against $281,109. The filing does not explain these changes. The nine-month net loss was $(24,720,556), narrower than $(26,932,586) in the prior-year period. That period included a tax benefit of $1,169,820, which the current period does not show, so the nine-month comparison is affected by that item as well as by the lower operating spend.

The balance sheet shows a weaker liquidity position. Cash and cash equivalents fell to $15,245,081 from $26,711,969 at December 31, 2025. Total assets declined to $18,571,942 from $30,494,083, and long-term debt of $11,733,350 at year-end 2025 is shown as '-' at September 30, 2026. Stockholders' equity rose to $13,495,140 from $9,251,833. The filing does not describe how the debt was settled or what funded the equity increase, though it does describe a PIPE financing of up to $22.3 million led by Nant Capital, LLC, whose initial closing was completed this quarter. The amount of that initial closing is not stated. The company's forward-looking statements name going concern risk, dependence on additional financing and Nasdaq minimum bid price compliance as risks.

The filing contains no revenue, segment, cash flow or forward guidance figures, so the read rests on the cost base, financing costs and balance sheet. Weighted average shares rose to 71,936,955 from 46,869,531 for the quarter, a figure that should be read alongside the per-share loss. The governance and pipeline items, including three new independent directors effective October 18, 2026, the NantWorks option on PDS0101 and the publication of VERSATILE-002 results, are reported as events and carry no financial figures in the filing.

Management, verbatim

During our third quarter, we continued to execute our strategic prioritization of PDS0301, our investigational tumor-targeted IL-12 immunocytokine, as our lead development program.

Frank Bedu-Addo, PhD, President and Chief Executive Officer, PDS Biotech

We believe the ongoing clinical trials of PDS0301 at the NCI, along with those of our cancer vaccine platform, support our view that targeted T cell immunotherapy has the potential to change how solid tumors are treated.

Frank Bedu-Addo, PhD, President and Chief Executive Officer, PDS Biotech

Not in the filing

stated, not guessed
  • Revenue: the filing reports no revenue line and no revenue figures.
  • Gross margin and cost of sales: not reported.
  • Guidance for any future period: not provided.
  • Prior-quarter (June 30, 2026) comparatives: not printed.
  • Percentage changes for net loss, operating expenses, interest expense and per-share loss: not printed.
  • Balance sheet comparatives at September 30, 2025 for cash, total assets and stockholders' equity: not printed. Only December 31, 2025 comparatives appear and are shown in balance_sheet_cash_flow.
  • Operating cash flow, investing cash flow, financing cash flow and free cash flow: not reported.
  • Amount of the initial closing of the PIPE financing: not stated (only the up-to $22.3 million total is printed).
  • Reason for the disappearance of long-term debt from the balance sheet: not explained.
  • Reason for the change in interest income and interest expense: not explained.
  • Consensus estimates, analyst expectations and share price reaction: not in the documents.
  • Segment data: the company reports a single business and no segment table.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

PDS Biotechnology Corp (Nasdaq: PDSB) is a clinical‑stage immunotherapy company focusing on IL‑12 immunocytokine and cancer vaccine platforms.

Company-level read

Ticker impact

$PDSBNeutralHigh confidence
Context

The 8‑K filing discloses Q3 2026 financial results, a $22.3 M PIPE financing, new board appointments and patent issuances, all first reported here.

Expected impact

potential downside as net loss expands, partially offset by financing support and trial updates

Evidence & confidence

Losses increased YoY, but the $22.3 M PIPE and exclusive license option to NantWorks provide near‑term liquidity and strategic upside.

Market effects

Biotech sector may see modest pressure as small‑cap earnings miss expectations, but financing activity could buoy peer funding sentiment.

U.S. biotech investors may adjust exposure to early‑stage immunotherapy firms.

Limited; the news is specific to a micro‑cap U.S. listed biotech.

Counterpoint

Despite the widened loss, the PIPE financing and exclusive license could enable a rapid clinical milestone, making the stock a potential rebound candidate.

Key entities

  • Nant Capital, LLC

    Lead investor in the $22.3 M PIPE financing.

  • Dr. Patrick Soon‑Shiong

    Founder of NantWorks, appointed to the board as a designee of Nant Capital.

Every PDSB earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$PDSBHighAI 8/10

B.Riley raises PDS Biotechnology stock price target on trial data

B.Riley raised its price target for PDS Biotechnology (PDSB) to $4.00 from $3.00, maintaining a Buy rating. The stock has gained 97% year-to-date, trading at $1.52. The upgrade follows positive trial data for PDS0301 in liver-metastatic colorectal cancer. PDSB plans to submit a Phase 3 protocol by Q4 2024, with a trial start in Q1 2027. The company also announced leadership changes and a share structure amendment.

$PDSBMedAI 8/10

PDS Biotechnology updates corporate presentation highlighting PDS0301 Phase 2 results, near-term data readouts

PDS Biotechnology updated its corporate presentation, reporting strong interim results for PDS0301 in combination with chemotherapy, including a 71.4% objective response rate and median OS exceeding 34 months in a Phase 2 mCRC trial. The company also highlighted upcoming data readouts and a planned Phase 3 protocol for PDS0301, as well as results for PDS0101 in a Phase 2 trial. PDS0101 is seeking partnerships for further development.

$PDSBMed

PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer

PDS Biotechnology (NASDAQ: PDSB) is planning a Phase III trial for PDS0301 in metastatic colorectal cancer. Early studies showed promising results, with a 70% response rate at six months. The company has discussed the trial design with the FDA and aims to start the trial in early 2027. PDS0301 is being evaluated in combination with hepatic artery infusion pump therapy, which showed durable responses and manageable side effects.

$PDSBMedAI 8/10

PDSB Jumps As JAMA Data And Nant Capital Deal Reshape The Story

PDS Biotechnology (PDSB) shares rose 13.08% on October 13, 2026, driven by positive clinical data and a financing deal. The company reported a 36% objective response rate in a Phase 2 trial published in JAMA Oncology, outperforming historical benchmarks. PDSB also secured $11.3M in funding from Nant Capital, though at a dilutive price. The stock's recent surge reflects optimism around its immunotherapy pipeline and strategic partnerships, despite its fragile financials.

$PDSBMedAI 8/10

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic…

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune

$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.